RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Sandra Bonache et al.|Annals of Oncology|2018Cited by 424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Cristina Cruz et al.|EMBO Molecular Medicine|2018Cited by 271
Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue XenograftsUrsula Kortmann, C. Blake Gilks, Hui Xue et al.|Clinical Cancer Research|2010Cited by 70